Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 May 20;33(15):1660-5.
doi: 10.1200/JCO.2014.57.3105. Epub 2015 Mar 2.

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)

Neal E Ready  1 , Herbert H Pang  2 , Lin Gu  2 , Gregory A Otterson  2 , Sachdev P Thomas  2 , Antonius A Miller  2 , Maria Baggstrom  2 , Gregory A Masters  2 , Stephen L Graziano  2 , Jeffrey Crawford  2 , Jeffrey Bogart  2 , Everett E Vokes  2
Affiliations
Clinical Trial

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)

Neal E Ready et al. J Clin Oncol. .

Abstract

Purpose: To evaluate the efficacy of maintenance sunitinib after chemotherapy for small-cell lung cancer (SCLC).

Patients and methods: The Cancer and Leukemia Group B 30504 trial was a randomized, placebo-controlled, phase II study that enrolled patients before chemotherapy (cisplatin 80 mg/m(2) or carboplatin area under the curve of 5 on day 1 plus etoposide 100 mg/m(2) per day on days 1 to 3 every 21 days for four to six cycles). Patients without progression were randomly assigned 1:1 to placebo or sunitinib 37.5 mg per day until progression. Cross-over after progression was allowed. The primary end point was progression-free survival (PFS) from random assignment for maintenance placebo versus sunitinib using a one-sided log-rank test with α = .15; 80 randomly assigned patients provided 89% power to detect a hazard ratio (HR) of 1.67.

Results: One hundred forty-four patients were enrolled; 138 patients received chemotherapy. Ninety-five patients were randomly assigned; 10 patients did not receive maintenance therapy (five on each arm). Eighty-five patients received maintenance therapy (placebo, n = 41; sunitinib, n = 44). Grade 3 adverse events with more than 5% incidence were fatigue (19%), decreased neutrophils (14%), decreased leukocytes (7%), and decreased platelets (7%) for sunitinib and fatigue (10%) for placebo; grade 4 adverse events were GI hemorrhage (n = 1) and pancreatitis, hypocalcemia, and elevated lipase (n = 1; all in same patient) for sunitinib and thrombocytopenia (n = 1) and hypernatremia (n = 1) for placebo. Median PFS on maintenance was 2.1 months for placebo and 3.7 months for sunitinib (HR, 1.62; 70% CI, 1.27 to 2.08; 95% CI, 1.02 to 2.60; one-sided P = .02). Median overall survival from random assignment was 6.9 months for placebo and 9.0 months for sunitinib (HR, 1.28; 95% CI, 0.79 to 2.10; one-sided P = .16). Three sunitinib and no placebo patients achieved complete response during maintenance. Ten (77%) of 13 patients evaluable after cross-over had stable disease on sunitinib (6 to 27 weeks).

Conclusion: Maintenance sunitinib was safe and improved PFS in extensive-stage SCLC.

Trial registration: ClinicalTrials.gov NCT00453154.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
CONSORT diagram. CR, complete response; PR, partial response; SD, stable disease.
Fig 2.
Fig 2.
Kaplan-Meier curve for progression-free survival after random assignment to placebo (n = 41) or sunitinib (n = 44). HR, hazard ratio.
Fig 3.
Fig 3.
Kaplan-Meier curve for overall survival after random assignment to placebo (n = 41) or sunitinib (n = 44). HR, hazard ratio.
Fig 4.
Fig 4.
An example of a partial response to chemotherapy that converted to a complete response on sunitinib. The tumor response to chemotherapy (chemo) plateaued after four cycles, but the tumor then responded to sunitinib for approximately 45 weeks.
Fig 5.
Fig 5.
A spider plot of RECIST tumor measurement on placebo before cross-over and then on sunitinib after cross-over.
See this image and copyright information in PMC

Comment in

References

    1. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(suppl 1):191–202. - PubMed
    1. Miller AA, Herndon JE, 2nd, Hollis DR, et al. Schedule dependency of 21 day oral versus 3 day IV etoposide in combination with IV cisplatin in extensive stage small cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B study group. J Clin Oncol. 1995;13:1871–1879. - PubMed
    1. Niell HB, Herndon JE, 2nd, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23:3752–3759. - PubMed
    1. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91. - PubMed
    1. Lara PN, Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–2535. - PMC - PubMed

Publication types

MeSH terms

Associated data